Antibe Therapeutics Inc
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSA… Read more
Antibe Therapeutics Inc (ATBPF) - Net Assets
Latest net assets as of December 2023: $25.94 Million USD
Based on the latest financial reports, Antibe Therapeutics Inc (ATBPF) has net assets worth $25.94 Million USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($56.36 Million) and total liabilities ($30.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $25.94 Million |
| % of Total Assets | 46.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | 439.81% |
| 10-Year Change | 1110.32% |
| Growth Volatility | 531.88 |
Antibe Therapeutics Inc - Net Assets Trend (2012–2023)
This chart illustrates how Antibe Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Antibe Therapeutics Inc (2012–2023)
The table below shows the annual net assets of Antibe Therapeutics Inc from 2012 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-03-31 | $40.17 Million | -29.33% |
| 2022-03-31 | $56.83 Million | +13.07% |
| 2021-03-31 | $50.26 Million | +1230.09% |
| 2020-03-31 | $3.78 Million | -49.21% |
| 2019-03-31 | $7.44 Million | -6.70% |
| 2018-03-31 | $7.98 Million | +124.44% |
| 2017-03-31 | $3.55 Million | -24.52% |
| 2016-03-31 | $4.71 Million | +1296.13% |
| 2015-03-31 | $337.19K | -89.84% |
| 2014-03-31 | $3.32 Million | +429.60% |
| 2013-03-31 | $-1.01 Million | -346.00% |
| 2012-03-31 | $-225.76K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Antibe Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12764218500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $141.49 Million | 352.26% |
| Other Comprehensive Income | $10.26 Million | 25.55% |
| Other Components | $18.90 Million | 47.06% |
| Total Equity | $40.17 Million | 100.00% |
Antibe Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Antibe Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mega Manunggal Property TBK PT
JK:MMLP
|
$10.98 Million |
|
Arcure SA
PA:ALCUR
|
$10.99 Million |
|
AMJ Global Technology
PINK:AMJT
|
$10.99 Million |
|
FuelPositive Corp
OTCQB:NHHHF
|
$10.99 Million |
|
Apexindo Pratama Duta Tbk
JK:APEX
|
$10.98 Million |
|
Vince Holding Corp. Common Stock
NASDAQ:VNCE
|
$10.98 Million |
|
M K Land Holdings Bhd
KLSE:8893
|
$10.98 Million |
|
GéoMégA Resources Inc
OTCQB:GOMRF
|
$10.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Antibe Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 56,833,000 to 40,166,000, a change of -16,667,000 (-29.3%).
- Net loss of 19,475,000 reduced equity.
- Other factors increased equity by 2,808,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.48 Million | -48.49% |
| Other Changes | $2.81 Million | +6.99% |
| Total Change | $- | -29.33% |
Book Value vs Market Value Analysis
This analysis compares Antibe Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.28x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-03-31 | $-0.09 | $0.22 | x |
| 2013-03-31 | $-0.39 | $0.22 | x |
| 2014-03-31 | $1.27 | $0.22 | x |
| 2015-03-31 | $0.09 | $0.22 | x |
| 2016-03-31 | $0.75 | $0.22 | x |
| 2017-03-31 | $0.37 | $0.22 | x |
| 2018-03-31 | $0.53 | $0.22 | x |
| 2019-03-31 | $0.35 | $0.22 | x |
| 2020-03-31 | $0.14 | $0.22 | x |
| 2021-03-31 | $1.35 | $0.22 | x |
| 2022-03-31 | $1.12 | $0.22 | x |
| 2023-03-31 | $0.77 | $0.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Antibe Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -48.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.76x
- Recent ROE (-48.49%) is above the historical average (-210.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-919.56K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-944.42K |
| 2014 | -80.76% | 0.00% | 0.00x | 1.31x | $-3.01 Million |
| 2015 | -1305.25% | -22053.26% | 0.03x | 2.34x | $-4.43 Million |
| 2016 | -55.89% | -59.30% | 0.46x | 2.07x | $-3.10 Million |
| 2017 | -161.70% | -63.46% | 0.84x | 3.02x | $-6.10 Million |
| 2018 | -93.16% | -87.31% | 0.68x | 1.57x | $-8.23 Million |
| 2019 | -172.24% | -134.36% | 0.64x | 1.99x | $-13.56 Million |
| 2020 | -511.83% | -193.67% | 0.72x | 3.66x | $-19.72 Million |
| 2021 | -52.33% | -270.78% | 0.12x | 1.63x | $-31.33 Million |
| 2022 | -44.09% | -258.00% | 0.11x | 1.57x | $-30.74 Million |
| 2023 | -48.49% | 0.00% | 0.00x | 1.76x | $-23.49 Million |
Industry Comparison
This section compares Antibe Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Antibe Therapeutics Inc (ATBPF) | $25.94 Million | 0.00% | 1.17x | $10.98 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |